Millipore Sigma Vibrant Logo
Atención: Nos hemos mudado. Los productos Merck Millipore ya no pueden adquirirse en MerckMillipore.comMás información

504377 AMPK Signaling Activator XIII, ZLN005 - CAS 4529-96-8 - Calbiochem

Calbiochem AMPK Activator, CAS 4529-96-8, inhibits luciferase activity, and activates AMPK signaling.

Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: Luciferase Inhibitor IV, 2-(4-tert-Butylphenyl)-1H-benzo[d]imidazole, 2-(4-(2-Methyl-2-propanyl)phenyl)-1H-benzimidazole

Primary Target: increases cellular ADP/ATP ratio via mitochondria respiration uncoupling
504377
Purchase on Sigma-Aldrich

Descripción

Replacement Information

Tabla espec. clave

CAS #Empirical Formula
4529-96-8C₁₇H₁₈N₂

Products

Número de referenciaEmbalaje Cant./Env.
5043770001 Frasco de vidrio 25 mg
Description
OverviewA cell-permeable benzimidazole that, in addition to its inhibitory potency against luciferase activity (IC50 <10 nM), also activates AMPK signaling by increasing cellular ADP/ATP ratio via mitochondria respiration upcoupling, effectively activating AMPK & PGC-1α in muscle, but not liver, cell types both in cultures (5-20 µM in rat L6 myotubes) in vitro and in db/db mice (15 mg/kg/day via p.o.) in vivo. Reported to improve glucose and insulin tolerance of db/db mice without any apparent effects on body weight or food intake.
Catalogue Number504377
Brand Family Calbiochem®
SynonymsLuciferase Inhibitor IV, 2-(4-tert-Butylphenyl)-1H-benzo[d]imidazole, 2-(4-(2-Methyl-2-propanyl)phenyl)-1H-benzimidazole
References
ReferencesZhang, L.N., et al. 2013. Diabetes. 62, 1297.
Product Information
CAS number4529-96-8
FormPinkish-white powder
Hill FormulaC₁₇H₁₈N₂
Chemical formulaC₁₇H₁₈N₂
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
ApplicationCalbiochem AMPK Activator, CAS 4529-96-8, inhibits luciferase activity, and activates AMPK signaling.
Biological Information
Primary Targetincreases cellular ADP/ATP ratio via mitochondria respiration uncoupling
Secondary targetluciferase activity inhibitor
Purity≥99% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Número de referencia GTIN
5043770001 04055977264043

Documentation

AMPK Signaling Activator XIII, ZLN005 - CAS 4529-96-8 - Calbiochem Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Referencias bibliográficas

Visión general referencias
Zhang, L.N., et al. 2013. Diabetes. 62, 1297.
Ficha técnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision20-September-2013 JSW
SynonymsLuciferase Inhibitor IV, 2-(4-tert-Butylphenyl)-1H-benzo[d]imidazole, 2-(4-(2-Methyl-2-propanyl)phenyl)-1H-benzimidazole
DescriptionA cell-permeable benzimidazole that, in addition to its inhibitory potency against luciferase activity (IC50 <10 nM), is reported to activate AMPK signaling by increasing cellular ADP/ATP ratio via mitochondria respiration uncoupling in a cell type-specific manner, effectively activating AMPK & PGC-1α in muscle, but not liver, cell types both in cultures (5-20 µM & 1-24 h in rat L6 myotubes; no effect in primary rat hepatocytes) in vitro and in db/db mice (gastrocnemius/calf muscle, but not liver tissue; 15 mg/kg/day via p.o. for 6 wks) in vivo. ZLN005 is orally available in mice (plasma Cmax & Tmax = 3.7 µM & 15 min, respectively, following single 15 mg/kg oral dosage to db/db mice) and is efficacious in improving glucose (1.5 g/kg i.p.) tolerance among 4-wk-treated and insulin (1 unit/kg) tolerance among 5-wk treated db/db mice (by 14% and 18%, respectively; 15 mg/kg/day via p.o.) in vivo without any apparent effects on body weight or food intake among db/db or non-diabetic controls.
FormPinkish-white powder
Intert gas (Yes/No) Packaged under inert gas
CAS number4529-96-8
Chemical formulaC₁₇H₁₈N₂
Structure formulaStructure formula
Purity≥99% by HPLC
SolubilityDMSO (50 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Standard Handling
ReferencesZhang, L.N., et al. 2013. Diabetes. 62, 1297.